An economic evaluation of schizophrenia : 1991.
In 1991, the costs for schizophrenia, which has a lifetime prevalence of 1.5% among adult Americans, totaled $65 billion.
Costs were broken down into their direct and indirect components.
Direct costs, which totaled $19 billion dollars, consisted of treatment-related expenditures such as those for inpatients and outpatients, as well as nontreatment-related expenditures such as those for the criminal justice system used by individuals with schizophrenia.
The direct costs were fairly similar to those of other recent estimates of the cost of schizophrenia.
Indirect costs, which were $46 billion dollars, included the lost productivity of both wage earners ($24 billion) and homemakers ($4.5 billion), individuals who were in institutions ($4.5 billion) or who had committed suicide ($7 billion), and caregivers who took care of schizophrenic family members ($7 billion).
Our method for calculating the indirect costs was slightly different than methods used in prior studies, which may account for our estimates being higher.
The method for determining each expenditure is provided, and the implications of these staggering costs are discussed.
Mots-clés Pascal : Schizophrénie, Psychose, Analyse coût, Economie santé, Etats Unis, Amérique du Nord, Amérique, Homme, Santé mentale, Coût indirect, Côut direct
Mots-clés Pascal anglais : Schizophrenia, Psychosis, Cost analysis, Health economy, United States, North America, America, Human, Mental health
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0487170
Code Inist : 002B18H05B. Création : 01/03/1996.